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Abstract 
Background and Aims: Recently we reported that direct injection of M1 macrophages significantly 
caused tumor regression in vivo. Despite the promising result, a major limitation in translating this 
approach is the induction of acute inflammatory response. To improve the strategy, a 
biocompatible scaffold for cell presentation and support is essential to control cell fate. Here, we 
aimed to elucidate the anti-tumor effects of a poly(ethylene glycol) diacrylate (PEGdA) and 
thiolated gelatin poly(ethylene glycol) (Gel-PEG-Cys) cross-linked hydrogels capsulated with M1 
macrophages in both in vitro and in vivo disease models. 
Methods: Hydrogels were made at 0.5% (w/v) Iragcure 2959 photoinitiator, 10% (w/v) PEGdA, and 
10% (w/v) Gel-PEG-Cys. Monocytic THP-1 cells were loaded into hydrogels and differentiated into 
M1 macrophages with lipopolysaccharide (LPS) and interferon gamma (IFN-γ). The M1 hydrogels 
were then cocultivated with HCC cell-lines Hep3B and MHCC97L to investigate the anti-tumor 
capacities and the associated molecular profiles in vitro. A nude mice ectopic liver cancer model 
with dorsal window chamber (DWC) and a subcutaneous tumor model were both performed to 
validate the in vivo application of M1 hydrogels.  
Results: M1 hydrogels significantly decreased the viability of HCC cells (MHCC97L: -46%; Hep3B: 
-56.9%; P<0.05) compared to the control in vitro. In response to HCC cells, the hydrogel 
embedded M1 macrophages up-regulated nitrite and tumor necrosis factor alpha (TNF-α) 
activating caspase-3 induced apoptosis in the tumor cells. Increased tumor necrosis was observed 
in DWC filled with M1 hydrogels. In addition, mice treated with M1 hydrogels exhibited a 
significant 2.4-fold decrease in signal intensity of subcutaneous HCC tumor compared to control 
(P=0.036).  
Conclusion: M1 hydrogels induced apoptosis in HCC cells and tumor regression in vivo. Continuous 
development of the scaffold-based cancer immunotherapy may provide an alternative and 
innovative strategy against HCC. 
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Introduction 
Hepatocellular carcinoma (HCC) is the fifth most 
commonly diagnosed malignancy and the second 
most common cause of death from cancer worldwide. 
The high metastatic rate and fatality of the disease 
(overall mortality to incidence ratio >90%) represents 
a major health issue. Currently, curative treatment 
options, including surgical and radiofrequency 
ablation, are only applied to the patients with limited 
tumor burden 1. Conventional chemotherapy has no 
significant impact on advanced HCC. As one of the 
predominant risk factors is sustained inflammation 
induced by chronic hepatitis or fibrosis, it is highly 
believed that the altered inflammatory milieu 
contributes significantly to the tumorigenesis 
progress. Therefore, combating the disease through 
an immunological interface is provocative as a novel 
therapeutic alternative. 
Cell-based immunotherapies are rapidly 
emerging as a promising treatment for many cancers 
in the last decade. Immunological cells including T 
cells, natural killer (NK) cells and dendritic cells have 
been experimented in clinical trials 2. Adoptive T cell 
transfer through the isolation and reinfusion of T 
lymphocytes into patients has shown anti-tumor 
potential against lymphoid leukemia 3-5. NK cells can 
be activated to produce abundant amounts of TNF-α 
and other inflammatory cytokines for the treatment of 
acute myeloid leukemia, non-Hodgkin lymphoma, 
and ovarian cancer 6-8. Due to the absence of tumor 
antigens and poor immunogenic tumor environment, 
most of these immunological cells require additional 
immuno-editing and ex vivo stimulation before further 
clinical applications. On the other hand, it is now 
widely believed that tumorigenesis is orchestrated by 
innate cellular mechanisms without the involvement 
of the adaptive immune system 9. 
Being a key member of the innate immunity as 
well as antigen presenting cells, macrophages with 
different heterogeneities exert opposing functions 
influencing the fate of tumor development and 
progression 10. In particular, tumor associated 
macrophages displaying the Th2 phenotype (M2) 
have significant roles in orchestrating tumor growth 
and metastasis. In contrast, the Th1 counterpart (M1) 
possesses pro-inflammatory and tumor suppressive 
properties. Accumulating evidences have shown that 
M1 macrophages can induce tumor rejection in 
various tumor models 11. In our recent study, we 
revealed the absence of tumoral M1 macrophages in 
HCC patients 12. Further in vitro and in vivo studies 
showed that the M1 populations suppressed HCC 
cells growth and induced liver tumor regression. Mice 
injected with M1 macrophages through portal vein 
injection exhibited a significant 2.79 fold reduction in 
tumor volume. Despite its anti-tumor effectiveness, 
acute inflammation leading to mortality was 
observed. It was speculated that such approach was 
highly inflammatory thus necessitate further 
modification for therapeutic development. The direct 
injection approach also lacks the ability to controllably 
retain the immune cells in the tumor site. Therefore, a 
biocompatible scaffold for cell retaining and 
localization of the released molecules is essential to 
improve such cell-based immunotherapeutic 
approach. 
Hydrogels are three-dimensional polymeric and 
hydrophilic networks which have been widely used 
for cell encapsulation and controlled release of 
therapeutic proteins, peptides, drugs and nucleic 
acids 13. In addition, the biomaterial has also been 
widely utilized to reconstitute 3D culture 
environment for studying cell-cell interactions and 
drug screening in various cancer models 14. A 
thiolated gelatin poly(ethylene glycol)(Gel-PEG-Cys) 
and poly(ethylene glycol) diacrylate (PEGdA) 
cross-linked hydrogel was selected as a biomimetic 
scaffold for local delivery of activated M1 
macrophages. PEG exhibits desirable biomedical 
properties such as protein resistance, low 
immunogenicity, and enhanced biocompatibility 
while gelatin contains cell-binding motifs, such as 
RGD oligopeptides, which support cell adhesion and 
proliferation. The physical characteristics of the 
biomaterial including stiffness, swelling, enzymatic 
degradation, 2D cell adhesion and 3D cell 
encapsulation were studied in details previously 15-16. 
In terms of biological functions, we have reported that 
these PEG-hydrogels loaded with mesenchymal 
stromal/stem cells (MSCs) leads to spatially and 
temporally controlled cellular presentation to wound 
sites while maintaining pluripotency and a favorable 
healing outcome 17-20. The encapsulated MSCs 
demonstrate extensive cytoplasmic spreading, the 
formation of cellular networks, and improved focal 
adhesion with the co-cultured of macrophages 17-19. 
Apart from displaying the active immunogenic effects 
and biocompatibility, the hydrogels have been shown 
to be a bio-scaffold permitting the release of the 
entrapped cells derived small molecules and 
cytokines to the surrounding environment 21-23. With 
such evidences, we speculate that the PEG-hydrogels 
is an ideal candidate for retaining M1 macrophages as 
well as exerting its tumor suppressive functions for 
our study. 
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By surrounding tumors with M1 hydrogels, we 
hypothesized that tumor regression might be resulted 
similar to the previous direct injection approach but 
with less adverse effects. Despite the significances of 
innate immunology in tumorigenesis, there is a lack of 
evidences elucidating the tumor killing capacities of 
innate cells based hydrogels. In the present study, we 
first validated the biocompatibility of the hydrogels 
for M1 macrophages and then investigated the 
anti-tumor potential of M1 macrophage-loaded PEG 
hydrogels on HCC tumoral cell-lines. Two HCC 
animal models including the real time intravital 
imaging system for examining tumor regression were 
employed. Furthermore, the M1 hydrogel derived 
molecules responsible for the tumor suppressive 
phenotypes were identified. With these evidences, we 
have developed a potential biomaterial platform to 
safely delivering and sustaining M1 macrophages for 
further developing such cell-based immunotherapy 
for cancer treatment. 
Materials and Methods 
Cell culture  
The human acute monocytic leukemia cell line 
THP-1, normal hepatic cell line MIHA and HCC cell 
lines were purchased from ATCC and maintained 
according to ATCC guidelines. For luciferase-labeling, 
MHCC97L (a kind gift from Liver Cancer Institute, 
Fudan University) cells were transfected with 
luciferase gene in pGL3 vector (Promega), and 
positive clones were selected according to luciferase 
activity in Xenogen In vivo Imaging System 100 
(Xenogen IVIS® 100, Xenogen Corporation). 
Hydrogel synthesis 
PEGdA/Gel-PEG-Cys composite hydrogel was 
synthesized following previously procedures with 
modifications 15-16. PEGdA was synthesized via 
acrylation of PEG-diol (MW 2kDA, Sigma-Aldrich) by 
reacting a dicholormethane (DCM) solution of 
PEG-diol with acryloyl chloride and triethylamine at a 
relative molar ratio of 1:4:4. The raw product was 
filtered with aluminum oxide and washed three times 
with 1N NaOH and the final product was precipitated 
in cold diethyl ether, dried under vacuum for at least 
2 days, and analyzed via reverse phase high 
performance liquid chromatography (10-100% 
acetonitrile at 1mL/min, elution time 13.2 minutes) 
and NMR for acrylation percentage (acrylation peaks 
at 6.0PPM). Only PEGdA with an acrylation 
percentage of 80% or more was used for this study. 
Gel-PEG-Cys was synthesized using 
N-hydroxysuccinimide-functionalized PEG 
(Bis-NHS-PEG) synthesized from via carbonate 
linkaged between PEG-diol (MW 2kDA, Sigma 
Aldrich) and N,N’-disuccinimidyl carbonate with 
4-(dimethylamino)pyridine as a catalyst. Gelatin was 
modified with L-cysteine by dissolving Bis-NHS-PEG 
(1.0g, 0.43mmol) in 5mL of dry 
N,N-dimethlyformamide. L-cysteine (0.08g, 
0.66mmol) was added to the Bis-NHS-PEG solution 
followed by addition of 110μL DIPEA. The reaction 
was kept under argon for 20 minutes then 1% gelatin 
(type B, 75 bloom, from bovine skin, Electron 
Microscopy Sciences, Hatfield, PA) in PBS solution 
was added (60mL) followed by a 1 hour stir at room 
temperature under argon protection at a pH of 8.0. 
The product was dialyzed (6-8kDa cutoff) for 2 days 
against double-distilled water and filtered through a 
0.22μm filter, snap frozen and lyophilized followed by 
analysis via NMR (thiol groups at 1.3PPM) and 
analysis of relative free thiol concentration via the 
Ellman test.  
M1 hydrogel preparation 
Hydrogel formulations were made in PBS to 
synthesize a 0.5% (w/v) Irgacure 2959 photoinitiator 
(BASF, Ludwigshafen, Germany), 10% (w/v) PEGdA 
and 10% (w/v) Gel-PEG-Cys sterile-filtered solution 
prepared and characterized as described previously 
15-16, 24. The procedures for the preparation of M1 
hydrogels used in vitro and in vivo studies was 
illustrated (Figure 1). For in vitro studies, a THP-1 cell 
suspension was added into the formulation at the 
desired number of cells. The formulations were then 
pipetted (100μL) into a 10mm glass-bottom Petri dish 
(In vitro Scientific) with a circular recess and then 
polymerized by exposing to UV light (λmax=365nm, 
100W/cm2) for 2 minutes. For M1 polarization, 
culture medium containing 640nM PMA was added 
to each dish incubated at 37oC for 6 hours and then 
150ng/mL LPS and 25ng/mL IFN-γ for another 18 
hours. M1 hydrogels were then transferred to 
experimental wells or inserts for further assays. For in 
vivo studies, THP-1 cells were polarized into M1 
macrophages prior to loading to hydrogels and 
experimentation on tumor bearing mice.  
M1 characterization in hydrogels 
For visualizing the hydrogel embedded 
macrophages, a monoclonal mouse anti-human CD68 
FITC antibody (1:100; Dako) was applied with 
standard immuno-fluorescent staining protocol. 
Afterwards, the stained population in hydrogels was 
observed through 2D and 3D-images reconstruction 
under CZ LSM 710 confocal system.  
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Figure 1. Schematic diagram illustrating the preparation of M1 hydrogel for in vivo and in vitro studies.  
 
Cytokine antibody array analyses 
The expression profiles of 12 different cytokines 
(Th1/Th2/Th17) in culture (M1 hydrogel, MIHA, 
MHCC97L and Hep3B) and coculture (M1 
hydrogel-MHCC97L, M1 hydrogel-Hep3B, M1 
hydrogel-MIHA) conditioned supernatants were 
determined using antibody based PathScan® 
Th1/Th2/Th17 Cytokine Antibody Array Kit (Cell 
Signaling). All procedures were performed according 
to the manufacturer’s instructions. 
In vitro treatment of HCC cells with M1 
macrophage-loaded hydrogels 
The treatment of M1 hydrogels to HCC cells was 
conducted using the non-contact coculture transwell 
system (Corning). THP-1 cells were added at the 
desired number in 100μl hydrogel and polarized to 
M1 macrophages as described above. After 
polarization, each M1 hydrogel was transferred to 
10mm 0.4-μm sized pores inserts and to 24-well cell 
culture plate seeded with MHCC97L, Hep3B or 
MIHA cell-lines (1x105 cells per well). Co-cultures 
were either conducted at various M1 macrophage 
concentrations for 4 days, or for 1-4 days at 5x105 M1 
macrophages/hydrogel. After co-culture, the 
supernatants were stored for analysis, and a 
LIVE/DEAD® (Invitrogen) stain was applied to the 
cells with subsequent imaging on a Nikon Eclipse 
TE300 microscope. Metabolic activities of the treated 
cells were determined using an MTT metabolic 
activity assay (Acros Organics). Briefly, a 5mg/mL 
solution of thiazolyl blue tetrazolium bromide in PBS 
was added to media at 10μL/mL and 1mL of the MTT 
media was added to each well and incubated at 37oC 
for 4 hours. Followed by the removal of the media, 
stained cells were solubilized with 1mL of DMSO on a 
plate shaker for 10 minutes and quantified via optical 
density at 570nm. 
Measurement of nitrite, IL-6 and TNF-α 
production 
Nitrite measurements were performed using the 
Griess reagent (G4410; Sigma) according to the 
manufacturer’s recommendation. Supernatants 
collected from co-cultures were incubated with a 1:1 
ratio with Griess reagent. After incubation for 15 
minutes, the plate was read on a spectrophotometer at 
540nm. With a standard curve, the nitrite 
concentration for each culture supernatant was 
determined. The level of IL-6 and TNF- α in each 
culture supernatant were also analyzed using 
Duoset® ELISA kits with corresponding assay 
antibodies (R&D Systems, Inc.). 
In vitro treatment of HCC cells with TNF-α, 
IL-6 and nitrite 
1x105 Hep3B, MHCC97L, and MIHA cells were 
treated with 850pg/mL recombinant IL-6 (R&D 
Systems, Inc.), 1,250pg/mL recombinant TNF-α (R&D 
Systems, Inc.), or 250nM nitrite (Absolute Standards, 
Hamden, CT) for 24 hours similar to their secretory 
level found in previous co-culture experiments. Cells 
were then stained and imaged with LIVE/DEAD® 
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stain followed by MTT metabolic activity assay.  
Gene expression analyses  
RNA was isolated from the treated Hep3B, 
MHCC97L, and MIHA cells by lysing the cells with 
0.5mL of TRIzol reagent (ThermoFisher Scientific). For 
the hydrogel embedded M1 macrophage, M1 
hydrogels were placed in liquid nitrogen and crushed 
into powder followed by the addition of TRIzol 
reagent. Followed by standard RNA isolation protocol 
using RNeasy Mini Kit (Qiagen), the total RNA was 
then reverse transcribed with iScriptTM cDNA 
synthesis kit (Bio-Rad) with the iCycler thermocycler 
(Bio-Rad). RT-PCR was performed on synthesized 
cDNA using a StepOnePlus Real-Time PCR System 
(ThermoFisher Scientific) using TaqMan Expression 
Assay Probes for IL-6, TNF-α, IDO1, and caspase-3. 
Data pertaining to mRNAs were collected 
quantitatively and the CT number was corrected by 
CT readings of the corresponding internal control 
glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). 
Western blot 
Proteins from HCC cell-lines were prepared 
using RIPA buffer (50mM Tris-HCl, 1mM EDTA, 0.1% 
SDS, 150mM NaCl, 1% NP40, 0.1% 
sodium-deoxycholate, pH 8.0). 10μg of protein lysates 
was separated by 12.5% SDS-PAGE and transferred to 
PDMF membrane (Millipore). After blocking with 5% 
non-fat milk, the membrane was incubated with 
caspase 3 (8G10), cleaved caspase 3 (Asp175) and 
cleaved PARP (Asp214) (Cell signaling) at 4°C for 16 
hours. A secondary antibody against goat (Santa Cruz 
Biotech) and rabbit (Cell signaling) IgG diluted 1:3000 
was added at room temperature for 1 hour. 
Corresponding band was revealed using the 
enhanced chemiluminescence system (GE healthcare 
Amersham Bio-sciences) and monitored with an 
LAS-1000 (FijiFilm). β-actin was used as a loading 
control. 
Real-time intravital imaging using dorsal 
window chamber implantation 
All animal studies were conducted according to 
the Animal Ordinance (Control of Experiments, Hong 
Kong) and the Institute’s guidance on animal 
experimentation. Detailed surgical procedures were 
as described previously 25. Briefly, the dorsal window 
chamber (DWC) consists of two titanium frames that 
bind together to form a saddle on the back of the nude 
mice and is attached using spacers, bolts and 
fastening nuts. A 'chamber' is formed after a 
transparent glass cover slip placed onto the attached 
saddle covering the exposed fascia containing vessels 
and secured using a sterile removable 'C' clip. The 
nude mice ectopic liver cancer model was established 
using HCC cells (MHCC97L). MHCC97L cells were 
labeled with fluorescence reporter (GFP) during 
transduction and then injected subcutaneously into 
the DWC from the opposing side to the glass 
cover-slip. 100μL of hydrogel containing either PBS or 
1x106 fluorescence labeled activated M1 macrophages 
was then injected directly adjacent to tumor nodule in 
DWC. 
The tissue structure surrounding the tumor 
nodule, such as collagen, was visualized through two 
photons secondary harmonic generation. The process 
of cancer cells invasiveness as well as the hydrogel 
embedded macrophages was kinetically observed 
through 3D-images reconstruction under CZ LSM 710 
confocal system. The excitation wavelength was 
800nm (two-photon system). The emission wave 
lengths of GFP from tumor cells were 500-550nm. The 
emission wave lengths from connective tissue and M1 
macrophages in hydrogels were 385-425nm. The 
objective lens was 20X.  
Tumor xenografts in BALB/c nude mice and 
hydrogels implantation 
Male athymic nude mice (BALB/c nu/nu, 4-6 
weeks old) were used for the subcutaneous tumor 
animal model. Surgical procedures were as described 
previously 12. Briefly, 2x106 MHCC97L cells tagged 
with luciferase, suspended in 0.2mL DMEM, were 
injected subcutaneously into the flanks of the mice. 
After 3 weeks of injection as the size of tumor reached 
approximately 3mm, the mice were divided into 3 
groups (Negative control: DMEM; Blank: hydrogel 
with PBS; M1 gel: hydrogel embedded with 1x106 M1 
macrophages; each group with 4 mice). 200μL of 
hydrogel was injected directly adjacent to tumor 
nodule weekly in the blank and M1 hydrogel group. 
Followed by the treatment, the tumor size of 
MHCC97L xenograft was monitored weekly by PE 
IVIS Spectrum in vivo imaging system (PerkinElmer). 
All mice were euthanized at week 4 and the size of 
tumor was measured and compared. 
Statistical analysis  
Comparisons of quantitative data between two 
groups were analyzed by unpaired Student’s t-test. 
P<0.05 was considered statistically significant with 
P<0.05 (*), P<0.01 (**). All analyses were performed 
with Graphpad Prism 5.0. 
Results 
Characterization of PEG-hydrogel embedded 
M1 macrophages 
Stimulated with LPS and IFN-γ, hydrogel 
embedded THP-1 cells displayed macrophage marker 
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CD68 with even cell distribution analyzed by 3D 
confocal microscopy (Figure 2A, Supplemental 
Video 1). Identical pro-inflammatory cytokine 
profiles between M1 macrophages culture and M1 
hydrogels were validated as secretory IFN-γ, TNF-α, 
and IL-8 were found in both conditioned supernatants 
(Figure 2B). Apart from cytokines, M1 derived 
nitrites, was also detected in both supernatants from 
M1 macrophages culture (25μΜ) and M1 hydrogels 
(15μM) (Figure 2C). These data suggested that 
PEG-hydrogel permitted cell activation, retained the 
immuno-phenotypes and functions of the M1 
populations.  
Proliferation suppressive effect of M1 
hydrogels on HCC cells but not MIHA cells 
With the treatment of M1 hydrogels, decreased 
viability of HCC cells in a dose and time dependent 
manner were observed. For the dose effect, hydrogels 
loaded with 5x105 and 1x106 M1 macrophages 
significantly reduced HCC cell metabolic viability 
(Hep3B: -31%; MHCC97L: -56%. P<0.01) and (Hep3B: 
-50%; MHCC97L: -64%. P<0.01) respectively 
compared to controls after 4 days of co-culture 
(Figure 3A-D). For the time effect, hydrogels loaded 
with 5x105 M1 macrophages significantly reduced 
viability of Hep3B (2 days: -31%; 3 days: -42%; 4 days: 
-53%. P<0.01) and MHCC97L (2 days: -29%; 3 days: 
-37%; 4 days: -62%. P<0.01) compared to controls after 
co-culture (Supplemental Figure 1A-D). 
In contrast to HCC cells, hydrogels loaded with 
5x105 M1 macrophages had no significant impact on 
normal hepatic cell line MIHA in terms of viable 
growth density (Figure 3E) and metabolic activity 
(Figure 3F). Taken together, we demonstrated that 
treatment of M1 hydrogel (5x105 cells; 4 days) 
specifically suppressed HCC cells viabilities but not 
hepatocyte cells (Figure 3G). 
Cytokine profiling and molecular analysis of 
HCC, MIHA and M1 hydrogels co-cultures 
To identify potential tumor suppressive 
cytokines derived from M1 hydrogels, cytokine array 
analysis were performed. Similar to M1 macrophages 
culture and M1 hydrogels, we first confirmed that the 
biomaterials had no effects on HCC cells in terms of 
cytokine secretion (Figure 2B and 4A). Importantly, 
supernatants of Hep3B and MHCC97L cells treated 
with M1 hydrogels (5x105 cells, 4 days) showed 
increase pro-inflammatory cytokines of IL-6 and 
TNF-α compared to non-treatment groups (Figure 
4A). Further ELISA analysis revealed that by 
increasing the number of M1 macrophages to 1x106 
per hydrogel, higher levels of IL-6 and TNF-α in the 
coculture supernatants were detected (P<0.01) (Figure 
4B). 
In addition, M1 hydrogels (5x105 and 1x106) 
induced the level of nitrite in the co-culture 
supernatants (Figure 4B). Apart from the dose effect, 
increased the incubation time of M1 hydrogels with 
HCC cells also induced IL-6, TNF-α, and nitrite in the 
co-culture supernatants (Figure 4C-D). Higher levels 
of IL-6, TNF-α, and nitrite in the co-culture 
supernatant of MIHA cells with M1 hydrogels were 
also observed (Figure 4E). 
Anti-tumor potentials of the identified M1 
hydrogel derived molecules 
Based on these findings, we further examined 
the tumor suppressive capacities of the identified 
molecules derived from M1-hydrogels. Using the 
concentrations consistent to previous ELISA analysis, 
treatment of Hep3B and MHCC97L cells with 
1250pg/mL TNF-α (Hep3B: -51%; MHCC97L: -33%. 
P<0.01) or 250nM nitrite (Hep3B: -39%; MHCC97L: 
-13%. P<0.01) for 24 hours demonstrated significant 
decrease in metabolic viability compared to untreated 
controls (Figure 5A-D). In contrast, similar treatment 
 
 
 
Figure 2. Characterization of M1 hydrogels. (A) Cross section of hydrogels loaded with differentiated THP-1 cells that were CD68 positive (green) with the nuclei 
stained with DAPI (blue). (B) Cytokine secretion profiles of M1 macrophages, M1 hydrogel, Hep3B, MHCC97L and MIHA cell culture supernatants. (C) Nitrite level 
in M1 macrophages culture and M1 hydrogel supernatants. The error bar represented as SD. **P<0.01. 
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of nitrite to MIHA cells had no effect on metabolic 
viability but a significant decrease of the cell viability 
treated with TNF-α or 852pg/mL IL-6 were observed 
(Figure 5E-F). 
Anti-tumor molecular mechanism of M1 
macrophage-loaded hydrogels  
In response to HCC cells, transcript analysis 
showed that hydrogels embedded M1 macrophages 
up-regulated TNF-α (Hep3B: 9.5 fold increase, 
P=0.0128; MHCC97L: 10.2 fold increase, P=0.0107), 
IL-6 (Hep3B: 5.8 fold increase, P=0.002; MHCC97L: 5.8 
fold increase, P=0.0093) and IDO1 (Hep3B: 2.7 fold 
increase, P=0.0061; MHCC97L: 2.3 fold increase, 
P=0.0487) compared to untreated controls (Figure 
6A). 
With the presence of M1 hydrogels, Hep3B cells 
up-regulated IL-6 (4.9 fold increase, P<0.0001), TNF-α 
(5.6 fold increase, P=0.0075) and caspase-3 (2.6 fold 
increase, P=0.0221). MHCC97L cells with similar 
treatment demonstrated a significant increase in IL-6 
(57.4 fold increase, P=0.0005) and caspase-3 (2.4 fold 
increase, P=0.0014) expression (Figure 6B-C). 
Interestingly, MIHA cells demonstrated a significant 
increase in TNF-α (4.9 fold increase, P=0.0232) and IL-6 
but not caspase-3 upon the treatment with M1 
hydrogels (Figure 6D). Further western blot analysis 
revealed that M1 hydrogels induced the activation of 
apoptotic caspase-3 and PARP in cleaved form in 
Hep3B and MHCC97L cells (Figure 6E). 
In vivo anti-tumor efficacy of M1 hydrogels  
To investigate the tumor suppressive potentials 
of M1 hydrogels, two animal models were applied. 
First, the ectopic nude mice liver cancer model with 
dorsal window chamber was established (Figure 7A). 
With confocal microscopy, the real time intravital 
images indicated that less metastasis and more 
necrotic area in the ectopic liver tumor were observed 
in the M1 hydrogel group compared to the untreated 
(negative control) and blank hydrogels group (Figure 
7B). Further 3D reconstructed images illustrated the 
intravital distribution of hydrogel embedded M1 
macrophages to the tumor (Figure 7C). 
Second, a subcutaneous HCC model for 
examining the tumor regression capacities of M1 
hydrogels was applied (Figure 8A). After 4 weeks of 
continuous treatment, the intensity of tumor 
luciferase signals in M1 hydrogel group were 
significantly decreased by 2.4-fold (23.2U±5.8) 
compared to untreated controls (54.9U±10.3) 
(P=0.036) (blank hydrogels group: 48.2U±10.3)(Figure 
8B-C). In terms of tumor volumes, 6.9-fold decrease 
were also observed in the mice treated with M1 
 
Figure 3. Dose dependent effects of M1 macrophage-loaded hydrogels on HCC and MIHA cells after 4 days of co-culture. (A) Live/dead images of Hep3B cells after 
the treatment with M1 hydrogels. (B) Corresponding normalized metabolic activity. (C) Live/dead images of MHCC97L cells after the treatment with M1 hydrogels. 
(D) Corresponding normalized metabolic activity. (E) Live/dead images of MIHA cells after the treatment with M1 hydrogels. (F) Corresponding normalized 
metabolic activity. (G) Comparison of normalized metabolic activity between MIHA, Hep3B, and MHCC97L cells after the treatments with M1 hydrogels. The error 
bar represented as SD. **P<0.01. 
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hydrogels (0.10cm3±0.04) compared to the untreated 
controls (0.7cm3±0.27) (P=0.037) (blank hydrogels 
group: 0.65cm3±0.29) (Figure 8D). Further 
proliferative and apoptotic staining suggested that 
M1 hydrogels reduced Ki-67 positive and increased 
TUNEL positive tumor cells indicating its tumor 
anti-proliferative and pro-apoptotic roles in vivo 
(Figure 8E). 
Discussion 
In the last decade, the advancement of 
biomaterial-based delivery systems in cancer 
therapies holds promising potentials13,14. Studies 
using the biomaterials as carriers for delivering 
nanoparticles, chemothearapeutic drugs, antibodies, 
antigen specific peptides and immunological cells 
show beneficial results with increased efficacy 
compared to the direct injection approach 14. In our 
prior work, M1 macrophages have been experimented 
both in vivo and in vitro revealing their anti-tumor 
significances against HCC. Here we aimed at 
improving such novel therapeutic strategy by 
applying synthetic ECM biomaterial consisting of 
cross-linked PEGdA and Gel-PEG-Cys as a carrier for 
tumor-local delivery of activated M1 macrophages. 
As such, this innovative approach is the first of its 
kind in a biomaterial immunological combinatorial 
therapy for HCC. 
In the present study, several novel insights with 
the advantages of the scaffold-based cancer 
immunotherapy over direct cell transfer were offered. 
First, we illustrated the anti-tumor activities of M1 
hydrogels in both in vitro and in vivo studies. Apart 
from the dose and time-dependent effects on 
inhibiting HCC cells, in situ M1 hydrogels also 
significantly induced tumor necrosis and diminished 
tumor volume in two animal models. Second, the M1 
 
Figure 4. Cytokine secretion profiles and molecular analysis of the co-culture supernatants of M1 hydrogels with HCC and MIHA cells. (A) Cytokine secretion 
profiles of HCC cells and M1 hydrogel co-culture supernatants. (B) Level of IL-6, TNF-α, and nitrite of co-culture supernatants of HCC cells with no hydrogels                
( ), blank hydrogels ( ), and hydrogels loaded with 2.5x105 ( ), 5x105 ( ), and 1x106 ( ) M1 macrophages. The level of IL-6, TNF-α, and nitrite during 4 
days co-cultivation of (C) Hep3B, (D) MHCC97L and (E) MIHA cells with no hydrogels ( ), blank hydrogels ( ), and hydrogels loaded with 5x105 M1 
macrophages ( ). The error bar represented as SD. *P<0.05, **P<0.01. 
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hydrogels displayed low immunogenicity, high 
biocompatibility and molecule release kinetics. In 
contrast to our previous direct portal vein injection 
approach, mice treated with M1 hydrogels did not 
show symptoms of acute inflammation or mortality 
while retaining the tumor killing phenotypes. 
Preliminary blood analysis showed that unlike the 1.5 
fold increased of IL-1α in the direct cell transfer 
group, the M1 hydrogels did not induce evaluation of 
the pro-inflammatory cytokine in circulation 
compared to untreated control. Third, M1 hydrogels 
exhibited minimum effects on non-tumorous hepatic 
cells showing its specificity towards tumors cells. 
Forth, we demonstrated the M1 activation of the 
gel-embedded monocytes with exogenous addition of 
IFN-γ and LPS. On the other hand, increased release 
of nitrite, IL-6 and TNF-α in the M1 hydrogels and 
HCC cells co-culture supernatants were found. These 
indicated that the permission for materials exchange, 
cell-to-cell interactions and signal transductions of the 
M1 hydrogel to its environment. Considering these 
advantages together with the ease of synthesis and 
formulation, it is very feasible to translate and extend 
M1 hydrogels to clinical applications for HCC 
treatment.  
For identifying the potential M1 derived tumor 
suppressive molecules and the underlying signal 
transduction pathway, we first confirmed that the M1 
hydrogels up-regulated nitrite, IL-6, TNF-α and IDO1 
upon the exposure to HCC cells. It was then shown 
that M1 hydrogel, TNF-α and nitrite caused HCC cell 
apoptosis via activating the caspase-3 signaling 
pathway. In addition, we discovered that 
up-regulation of IDO1 could be also induced by 
TNF-α in dose dependent manner (data not shown). It 
is reported that elevated nitrite levels can induce the 
cleavage and activation of caspase-3 with subsequent 
cleavage of PARP-1 that ultimately leads to apoptosis 
through a mitochondria-dependent death pathway 
26-27. Based on the current knowledge and 
experimental evidences, here we proposed an 
anti-tumor mechanism of M1 hydrogels. Increased 
levels of TNF-α during the treatment of M1 hydrogels 
to HCC cells promoted IDO1 expression in M1 
macrophages leading to the secretion of nitrite and 
subsequently activated caspase-3 dependent 
apoptosis in the tumor cells (Figure 9). 
 
 
Figure 5. Tumor suppressive effects of IL-6, TNF-α and nitrite in HCC. (A) Hep3B live/dead images and (B) Corresponding normalized metabolic activity. (C) 
MHCC97L live/dead images and (D) Corresponding normalized metabolic activity. (E) MIHA live/dead images and (F) Corresponding normalized metabolic activity. 
The error bar represented as SD. *P<0.05, **P<0.01. 
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Figure 6. Anti-tumor molecular mechanism of M1 hydrogels against HCC. (A) Gene expression of IL-6, TNF-α, and IDO1 in gels embedded M1 macrophages after 
coculture with Hep3B, MHCC97L and MIHA cells. Gene expression of IL-6, TNF-α, and caspase-3 in (B) Hep3B, (C) MHCC97L, and (D) MIHA cells after co-culture 
with no hydrogels, blank hydrogels, and M1 hydrogels (5x105). (E) Western blot analyzes of cleaved caspase-3, caspase-3 and PARP in HCC cells after co-culture with 
no hydrogels, blank hydrogels and M1 hydrogels (5x105). The error bar represented as SD. *P<0.05, **P<0.01. 
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Figure 7. In vivo study of the anti-tumor effects of M1 hydrogels (1x106) in HCC tumors (MHCC97L-GFP) in a window-chamber model. (A) Window-chamber model 
setup of tumor nodule with the injection of polymerized M1 macrophage-loaded hydrogels. (B) Real-time intravital imaging of the tumors 1-3 days after the injection 
of M1 hydrogels. Tumor necrosis area indicated by white dashed line (C) Three-dimension reconstructed images of the injected site at day 3. 
 
Interestingly, in contrast to TNF-α and nitrite, 
our study showed that up-regulation of IL-6 were not 
cytotoxic to HCC cells. Studies suggested that IL-6 
autocrine production is critical for HCC progression 
acting as a risk indicator for adverse prognosis 28-29. 
IL-6 enhances orosphere formation, p-STAT3 
activation, survival, and self-renewal of human cancer 
stem cells (CSCs) 30. Recently, it is reported that tumor 
associated macrophages derived IL-6 is highly 
correlated with the occurrence and development of 
HCC via activating anti-apoptotic STAT3 pathway 31. 
In the present study, it is possible that the HCC cells 
attempted to utilize the M1 macrophage populations 
to assist in its own survival. Based on the findings, we 
speculated a paracrine feedback loop between M1 
hydrogels and HCC cells for the pro- and anti-tumor 
phenotypes. Identifying such communications could 
be useful for mimicking the stimulatory signals and 
further enhancing the anti-tumor efficacy of the 
biomaterial. 
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Figure 8. In vivo analysis of the anti-tumor effects of M1 hydrogels on tumor growth and histology of HCC tumors (MHCC97L-Luciferase) in a subcutaneous tumor 
model. (A) Subcutaneous tumor model setup of tumor module with the injection of polymerized M1 macrophage-loaded hydrogels adjacent to the tumor. (B) 
Measurements of mean in vivo subcutaneous tumor bioluminescence of each group over 4 weeks. Bioluminescent signals were quantified as photons/s at each imaging 
time point. (C) Monitoring of in situ tumor growth by PE IVIS Spectrum at week 1–4. Following euthanasia at week 4, (D) the examination of tumor volume. (E) Ki-67 
and TUNEL staining of liver tumor tissues in each mouse. n = 4. *P<0.05. The error bar represented as SEM. M1: 1x106 M1 macrophage loaded hydrogels; B: blank 
hydrogels; C: no hydrogels (control).  
 
Figure 9. Schematic diagram of proposed anti-tumor molecular mechanism of M1 hydrogel.  
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In summary, we explored a new novel 
therapeutic strategy utilizing biomaterial engineering 
and immunology. The anti-tumor functionality, 
specificity and biocompatibility of M1 hydrogels were 
demonstrated both in vitro and in vivo studies. 
Localization of activated M1 macrophages to the 
tumor through encapsulation in hydrogels may 
provide an alternative and innovative treatment 
option against HCC. 
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